Compare SABS & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | USAU |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9M | 242.1M |
| IPO Year | 2020 | 2020 |
| Metric | SABS | USAU |
|---|---|---|
| Price | $3.29 | $10.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $11.64 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 634.0K | 150.8K |
| Earning Date | 11-05-2026 | 12-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.53 | 36.11 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,402,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.44 | $10.44 |
| 52 Week High | $5.15 | $23.72 |
| Indicator | SABS | USAU |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 28.23 |
| Support Level | $2.44 | N/A |
| Resistance Level | $4.06 | $16.45 |
| Average True Range (ATR) | 0.23 | 0.64 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 92.47 | 6.23 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.